Patent intelligence · US
US 9205094
Compositions comprising bile acid sequestrants for treating esophageal disorders
Compositions comprising bile acid sequestrants for treating esophageal disorders
Patent details — US 9205094
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 8, 2015
- Expiration
- Dec 3, 2035
- Applicant
- IRONWOOD PHARMACEUTICALS, INC.
- Claims
- 12
- CPC classes
- A61K, A61K31/195, A61K31/27, A61K31/341
Quick answer
US 9205094 (Compositions comprising bile acid sequestrants for treating esophageal disorders) is held by IRONWOOD PHARMACEUTICALS, INC.. Status: granted. Granted Dec 8, 2015. Expires Dec 3, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IRONWOOD PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/195, A61K31/27, A61K31/341, A61K31/4164, A61K31/4184
More from IRONWOOD PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 10702576
Stable formulations of linaclotide
granted -
US 10675325
Stable formulations of linaclotide
granted -
US 10618938
Compositions for colon cleansing and the treatment of gastrointestinal disorders
granted -
US 10266529
Salts, co-crystals, and polymorphs of an anxiolytic compound
granted -
US 10189809
SGC stimulators
granted -
US 10183021
sGC stimulators
granted -
US 10047095
sGC stimulators
granted -
US 9969742
Imidazotriazinone compounds
granted
Frequently asked questions
What is US patent 9205094?
US 9205094 (Compositions comprising bile acid sequestrants for treating esophageal disorders) is held by IRONWOOD PHARMACEUTICALS, INC.. Status: granted. Granted Dec 8, 2015. Expires Dec 3, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9205094?
IRONWOOD PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 45 pharmaceutical patents for this assignee.
When does US 9205094 expire?
Our index shows an expiration date of Dec 3, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.